A systematic review and meta-analysis of randomized controlled trials, juxtaposing the control of glycemia and blood pressure between large dose empagliflozin and placebo among type 1 diabetes patients
Abstract
Objectives: While empagliflozin (25 mg) is used to treat type-2 diabetes mellitus patients with optimum renal functioning, its efficacy and safety in type-1 diabetes mellitus (T1DM) is not yet established. Therefore, this study aimed to compare insulin-treated T1DM patients’ (with adequate renal functioning) glycemic and blood pressure control between the 25 mg empagliflozin recipients and placebo recipients. Methods: Parallel-arm randomized controlled trials comparing the effect of daily administered 25 mg empagliflozin tablets in adjunct to insulin treatment with placebo and insulin treatment in T1DM patients with an estimated glomerular filtration rate of 45 mL/min/1.73 m2 or more were eligible for inclusion. Trials were searched in PubMed, EMBASE, SCOPUS, and CENTRAL with no restriction on date and language. Risk of bias of trials was assessed and mean and standard deviation of glycated hemoglobin (HbA1c, in %), systolic blood pressure (mmHg), and diastolic blood pressure (mmHg) at the end of the trial period were collected, and random-effects meta-analysis was done to estimate the weighted mean difference (WMD). The meta-analysis was done in Stata statistical software. This study was conducted in June 2019. Results: Three relatively small-sized trials published between 2015 and 2018 were eligible for review and analyses. The trials suffered from unclear risk of performance and detection bias. The HbA1c reduction favored the intervention group (WMD = −0.478, 95%…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.